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expression, FA, and the presence and/or severity of Coronary Artery Disease (CAD). 
Methods: Patients, prospectively enrolled, had blood drawn and analyzed for: gene PMs 
(PCRIRFLP: t-PA. Alu repeat; urokinase, BamHI; PAI-1, Hindlll; fibrinogen, Haelll; 
MTHFR, Hinfl). plasma levels of FPs (ELISA: t-PA, PAI-1, u-PA). fibrinogen (clotting 
assay), FA (PAP assay), Lp(a) and homocysteine. The absence/presence and severity of 
CAD was determined by angiographic analyses; medical histories included risk factors. 
Data were analyzed by logistic regression, multivariate analysis and combined risk factor 
interactions. _ 
Results: Of the 1107 patients enrolled (57% male, 70% Caucasian, age 19.88 yrs), 465 
(21%) had no CAD. Factors associated with CAD presence were: U-PA PM, age, smok- 
ing, Lp(a), hypercholesterolemia. PAI- activity/antigen and a combined U-PA and fibrin- 
ogen PM interaction and gender/age interaction. Factors associated with CAD severity 
were: U-PA PM, age, smoking, hypercholesterolemla, diabetes, BMI, t-PA antigen. Lp(a) 
and a combined u-PA and fibrinogen PM interactton, u-PA and t-PA PM interaction, u-PA 
and MTHFR PM interaction and a gender/race Interaction. The u-PA PM, independently 
and/or in association with other FP PMs. was associated with plasma levels of FA, PAI- 
antigen/activity and fibrinogen, but not u-PA.Conclusions: 1) The u-PA PM appears to 
be associated with the development and progression of CAD; 2) A significant interaction 
exists between various FP PMs, particularly the u-PA PM, in determining plasma FP lev- 
els and FA; 3) Lack of association between the u-PA PM and plasma u-PA levels sug- 
gests that regulation of plaque-localized expression of u-PA is important. These results 
suggest a potential role for FPsiFA and FP gene interactions in the development and 
progression of CAD with age. 
1032-l 25 Plasma PAI- Antigen Concentration Predicts Clinical 
Outcome of Thrombolytic Treatment of Acute 
Myocardial Infarction 
Aaata Mlvnarska, Tomasz Waszyrowski, Jaroslaw D. Kasprzak, Jonscher Hospital. 
Lodz, Poland, Institute of Internal Medicine, Medical University of Lodz, Lodz, Poland 
Background: Plasmlnogen activators inhibitor type 1 (PAI-1) is the most important regula- 
tory element in fibnnolytic system, and may be involved in the efficacy of fibrinolytic treat- 
ment for acute myocardial infarction (AMI). 
Aim: The study aimed lo elucidate the association between plasma PAI- antigen con- 
centration (PAS) and activity (PAct) before and after standard streptokinase (STK) infu- 
sion and clinical outcome in patients (pts) with AMI. 
Material and methods: The studied group consisted of 82 pts with AMI with ST elevation 
(aged 61.0+9.0 yrs. 26 females, 56 males) treated with STK. Plasma PAg and PAct were 
measured before, immediately after and 1,2,3,4,5 hours after STK infusion using com- 
mercially available ELISA tests (Biopool, Sweden). Clinical outcome (mortality, reperiu- 
slon and reocclusion rate) was analyzed during mean follow-up of 59 weeks (range I- 
96). Kaplan-Meier curves for overall survival (OS) and event-free survival (EFS) were 
calculated according to PAg concentration. 
Resulb: Peak increase in PAg and PAct was demonstrated after STK treatment in the 
3rd hour. Therefore, PAg and PAct at admission to hospital (PAgO. PActO) and 3 hours 
after STK (PAg3, PAct3) were further analyzed. PAg3 and PAct3 were significantly 
higher as compared to PAgO and PActO (30.0+13.3 vs. 20.8i8.6 ng/ml, p=O.O01 and 
37.3+13.7 vs. 10.0*11.2 IU/ml, p<O.OOOl, respectively). PAg3 values were increased in 
pts who died during follow-up (n=l5)(40.8*3.3 vs. 24.7i14.2 ng/ml, p=O.O38) and in pts 
without reperfuslon (36.5tll.4 vs. 20.3r12.6 @ml, p=O.O29). Threshold value of PAg3 
predictive for no repedusion, calculated using ROC curve analysis, were 21.8 ng/ml 
(sew. 77%, spec. 59%, area under the ROC curve 0.65) and for fatal outcome 33.3 ngl 
ml @ens. 90%, spec. 66%, area under the ROC curve 0.70). The probability of survival of 
pts with PAg3 over and below 33.3 ng/ml was 65% and 97% respectively (p=O.O0016). 
There was no significant difference in PActO and PAcl3 between groups separated con- 
cerning mortality, repedusion and reocclusion. 
Conclusions: Plasma PAI- antigen concentration over 33.3 nglml in the 3rd hour after 
fibrinolytlc treatment of AMI predicts unfavorable clinical outcome. 
1032-I 26 Thrombin Potentiates Platelet-Derived Growth Factor 
Induced Vascular Smooth Muscle Cell Proliferation via 
PI3 Kinase Activation and p27 Downregulation 
Karin Frischknecht Helen Greutert, Thierry P. Carrel, F&x C. Tanner, Untversity 
Hospital Bern, Bern, Switzerland 
Thrombus formation and vascular smooth muscle cell (VSMC) proliferation are key 
events in the pathogenws of vascular diseases. Mediators from both platelets such as 
PDGF and the coagulation system such as thrombin can affect VSMC proliferation. 
Thus, we examined whether PDGF and thrombin interact at the level of VSM cell cycle 
regulation. When human saphenous vein VSMC were stimulated with a maximal concen- 
tration of thrombin (3 U/ml), no significant increase !n cell number was observed over 4 
days. In contrast, thrombin potentlated threshold concentrations of PDGF-BB (1 nglml) 
(increase in cell number: thrombin alone 4’375&‘105; PDGF alone 5’375i2’057; throm- 
bin plus PDGF 18‘688~1’711; p=n.s. for thrombin vs. PDGF; pcO.0002 for thrombin or 
PDGF vs. thrombln plus PDGF; n=4). SH-thymidine incorporation revealed that potentia- 
tion did also occur with ten times lower thrombin concentrations (n=6). Potentiation was 
prevented by hirudin (3 U/ml). Thrombin did not alter PDGF c( or p receptor expression 
as determined by FACS analysis. Thus, expression of cell cycle proteins regulating Gl 
progression was determined by Western blotting for up to 30 hours of mitogenlc stimula- 
tion. The cyclin-dependent kinase inhibitors ~21, ~27, and p57 were neither affected by 
thrombln nor PDGF alone. In contrast, thrombin plus PDGF caused p27 downregulatlon, 
while ~21 was slightly Induced. and p57 remained unaffected. Expression of cyclin- 
dependent kinase 2 (cdk2) and cyclln E was not affected under all these conditions. 
CdkP activity was neither affected by thrombin nor PDGF alone, but enhanced by throm- 
bin plus PDGF. This increase in cdk2 activity was prevented by hirudin. Inhibition of PI3 
kinase by LY294002 prevented p27 downregulatlon In response lo thrombin plus PDGF. 
Thrombin alone did not activate AkVPKB, while activation by PDGF alone was identical 
to that by PDGF plus thrombin. Thus, thrombin IS not mitogenlc for human saphenous 
vein VSMC, but strongly potentiates VSMC proliferation to PDGF in a dose-dependent 
manner. This potentiation is related to activation of PI3 kinase, and results in Akt/PKB 
independent downregulation of the CKI ~27. 
1032-127 Tissue Factor Pathway in Carotid Atherosclerotic 
Plaques: Relationships With Clinical Patterns and Risk 
Factors 
Christophe Zawadzki, Stephan Haulon, Sophie Susen, Andre Vincentelli, Emmanuelle 
Jeanpierre, Christian Lucas, Enc Van Belle, Florence Richard, Delphine Corseaux, 
Brigitte Jude, HBpital Cardiologique, Lille, France, lnstitut Pasteur. Lille, France 
Background: Tissue Factor (TF) and its inhibitor, the tissue factor pathway inhibitor 
(TFPI) probably play an Important role in the thrombogenicity of atherosclerotic plaques 
but the factors regulating their expression are poorly known. 
Methods TF,TFPI and activated factor VII (F Vlla) levels were measured in the athero- 
sclerotic plaques of 100 consecutive patients undergoing carotid endartereclomy. A mul- 
tiple linear regression model was used lo test the relationships between TF, TFPI and 
FVlla with 1) documented history of ischemic cerebral events (ICE), 2) conventional car- 
diovascular risk factors, 3) markers of inflammation (fibrinogen, interleukin-6, CRP) and 
coagulation activation (thrbmbin-antithrombin complexes, D-dimers) and metabolic syn- 
drom (Body mass index (BMI), insulinemia, triglyceridemia) and 4) plaque morphology 
(presence or absence of a massive lipid-rich core). 
Results : Plaque TF activity. TFPI antigen and FVlla were strongly correlated with each 
other. TF and TFPI but not FVlla were higher in the 40 symptomatic than In the 60 
asymptomatic patients (TF :1.82*0.32 vs 1.02*0.29 mlfigramme of plaque, median+ 
[95%CI]., p=O.O08 and TFPI :53.50*11.36 vs 20.6Oi7.92 pg/g, p=O.OOOl, respectively). 
The distribution of traditional cardiovascular risk factors was not different between 
asymptomatic and symptomatic subjects. TF activity was higher and TFPI was lower in 
men than in women. The plasma CRP level was a strong independent predictor for 
plaque TF activity. BM1>25 and maswe lipid rich core were positive predictors and 
hypertriglyceridemia was negative predictors for plaque TFPI. 
Conclusion : In carotid plaques, TF and TFPI levels were higher In patlents with a docu- 
mented history of ICE. TF is strongly related to the inflammatory process while TFPI is 
dependent of the presence of a massive lipid core and of markers of the metabolic syn- 
dram. 
1032-l 28 Novel Role for the Membrane-Bound Chemokine 
Fractalkine: A Pathophysiologlcally Relevant 
Mechanism in Platelet Activation and Adhesion 
Andreas Schaefer, ChristIan Schulz, Martin Eigenthaler, Daniela Fraccarollo, Meinrad 
Gawaz, Georg Ertl, Ulrich Walter, Johann Bauersachs, Medizinische Universltaetsklinik 
Wuerzburg, Wuerzburg, Germany, Deutsches Herzzentrum Muenchen, Munich, 
Germany 
Background: Chemokines released by the endothelium have pro-aggregatory properties 
on platelets. Fractalkine, a recently dwovered membrane-bound chemokine with a 
transmembrane domain, is expressed in vascular injury, however, the effects of fractalk- 
Ine on platelets have not yet been investigated. 
Methods and Results: Blood was taken from healthy Wistar-Kyoto-rats and the expres- 
slon of the fractalkine-receptor on platelets was demonstrated. The modulation of sur- 
face-expression of P-selectin, a reliable marker of platelet activation, was assessed by 
flow cytometry. P-selectin expression was significantly enhanced by in vitro stimulation 
with recombinant rat fractalkine (FR: 60.4i7.7 mfu [mean fluorescence units]) as com- 
pared with baseline levels (BL: 21.6*2.9 mfu. p<O.OOl). Preincubation with either the 
nitric oxide-donor sodium nitroprusside (SNP) or the cyclooxygenase inhibitor acetyl sail- 
cylic acid (ASA) prevented the fractalkine-induced Increase in surface P-seledin expres- 
sion. Selectively inhibiting the function of recombinant fractalkine by an antagonizing 
antibody (anti-FR) or the dlsruption of the G-protein coupled intracellular signaling cas- 
cade of the fractalkine receptor by pertussis toxin (PTX) completely prevented fractalkine 
mediated platelet activation and adhesion (antl-FR: 15.2eO.9 mfu; PTX: 19.8e3.1 mfu, 
p<O.OOl vs. FR). 
In an adhesion flow chamber stimulation wth fractalkine significantly enhanced platelet 
adhesion to collagen and fibrinogen by 20% and 60% respectively. Similar to P-selectin 
expression, enhanced adhesion could be prevented by the antagonizing antibody or pre- 
incubation of platelets with PTX. 
Conclusion: The membrane-bound chemokine Induces platelet activation and adhesion. 
As fractalkine is overexpressed in atherosclerosis and vascular injury it IS likely to sub- 
stantially contribute to increased thrombogenesis in vascular diseases. 
1032-l 29 Mineralocorticoid Receptor Antagonism Attenuates 
Thrombotic Response to Injury in Atherosclerosis 
Through Favorable Effects on Nitric Oxide 
Bioavailability 
Saniav Raiaaopalan, Peter Bodary, Damon Duquaine, Bertram Pitt, Dame1 Eitzman, 
University of Michigan, Ann Arbor, Ml 
Background: Recent studies have demonstrated favorable effects of mlneralocorticoid 
receptor (MR) blockade in conditions associated with up-regulation of the renln-angio- 
tensin axls. We hypothesized that spironolactone modulates thrombotlc response to 
injuly in a genetlc model of hyperlipidemia. 
Methods: LDL receptor knock out mice (LDLR-‘-) were implanted with spironolactone (35 
mgJkg/day) or placebo pellets at 6 weeks while on high lipid chow (5-8 animals/group). At 
18 weeks, vasomotor responses were assessed in aortas, with measurement of time to 
thrombosis after photochemical carotid artery injury. Aldosterone infused animals served 
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as additional controls. Results: Responses to acetylcholine (Ach) and A23187 were 
improved with spironolactone (Table 1) while responses to (endothelium Independent) 
agonist nitroglycerin and phenylephrine remained unaltered (pk relsxation of 100 * 3 vs. 
100 * 3% and constriction of 103 r 22 vs. 108 * 19% in placebo vs. spironolactone 
respectively. 
Table 1. 
Ach 
Pk Relaxation(%) ED, 
A23187 
Pk Relaxation (%) ED,, 
LDLR” Placebo 67.3 * 8.1 7.5 * 0.21 74.8 + 2.6 7.4 * 0.1 
LDLR”. Spiro 103.8 * 6.4 7.6 * 0.10 92.0 + 2.5’ 7.6 * 0.4 
‘=pcO.Ol vs. placebo, 
Time to thrombosis was decreased with aldosterone infusion (13+2 vs. 23+2 minutes in 
controls, ~‘0.05 by ANOVA) while spironolactone administration prolonged time to 
thrombosis (28+2 vs. 23~2 minutes. ~~0.05 by ANOVA). 
Conclusion: MR antagonism improves endothelial function and attenuates thrombotic 
response to injury while aldosterone potentiates thrombotic response to injury. These 
findings indicate an emerging role for aldosterone receptor antagonists in atherosclero- 
sis. 
1032-l 30 Short-Term Effect of Oral Anticoagulant Therapy on 
Documented Left Atrial Thrombi in Candidates for 
Percutaneous Transvenous Mitral Commissurotomy 
Sonakwan Silaruks, Bandit Thinkhamrop, Songsak Kietchoosakul, Chaiyaslth 
Wonvipaporn, Pyatat Tatsanavivat, Vlrat Klungboonklong. Khon Kaen University, Khon 
Kaen. Thailand 
Background: The presence of left atrial thrombus (LAT) in mitral stenosis pabents is a 
contraindication to percutaneous transvenaus mitral commlssurotomy (PTMC). Although 
resolution of LAT after long-term oral anticoagulant therapy has been documented, its 
short-term effect, which would be more clinically important, has been less clearly estab- 
lished. 
Objectives: To estimate the disappearance rate of documented LAT among candidates 
for PTMC who were treating with oral anticoagulation for 6 months and to determine its 
significant predictors. 
Design: Prospective cohort study 
Methods: Between August 1996 and February 2002, a total of 687 consecutive PTMC 
candidates underwent both transthoracic and multiplane transesophageal echocardio- 
graphic studies (TTE. TEE). Of these, 219 pabents demonstrated LAT by TEE and were 
given oral anticoagulation (INR 2.0 to 3.0). The fate of LAT was studied at 6 months 
using both TTE and TEE. 
Results: Among 219 PTMC candidates with LAT (mean age 39.6+7.4 years, range 19-62 
years; 73% females), complete resolution of LAT was demonstrated in 53 cases at the 
first 8th.month follow-up, with an overall disappearance rate of 24.2% (95%CI: 18.5% to 
29.9%). All 53 patients subsequently underwent successful PTMC. None of the cases, 
with LAT in the atrial body (n=27), had LAT resolution. Among the 168 patients whose 
LAT persisted, the LAT swe had nevertheless been reduced by approximately 20% from 
the baseline (p<O.OOi). By using multiple logistic regression analysis, the significant pre- 
dictors associated with LAT resolution included a NYHA Class of 1 or 2 (OR=ll.ll: 
95%Cl=3.23. 33 33), a LAT size cl.6 cm2 at the first study (16.87: 5.56, SO.OO), a fixed 
LAT (4.35: 1.49, 12.5), a left atial spontaneous echo contrast of less than or equal to 
Grade 1 (3.45: 1.20, lO.O), and an INR of more than or equal to 2.5 (19.53: 3.37, 113.16). 
Conclusions: About a quarter of PTMC candidates wth LAT could awd heart surgery by 
safely undergoing PTMC after 6 months of oral anticoagulant therapy as their LAT had 
disappeared. Less clinical severity, presenting as a small and fixed LAT, less grading of 
the left atrial spontaneous echo contrast, and a tolerance to high INR, could enhance 
such an outcome. 
1032-131 The Role of Endothelial-Derived Hyperpolarizing Factor 
in Tissue-Type Plasminogen Activator Release 
James A. Muldownev. Ill, John R. Falck, Nancy J. Brown, Douglas E. Vaughan, 
Vanderbilt University Medical Center, Nashville, TN, University of Texas-Southwestern, 
Dallas, TX 
Physiologic release of tissue-type plasmmogen activator (t-PA) from the endothelium is 
critical for vascular homeostasis. and IS prostacyclln and nitric oxide-independent in 
humans. Prewously, we have suggested that endothellal-derived hyperpolarizing factor 
(EDHF) may play a role in t-PA release. EDHF promotes endothelial-dependent smooth 
muscle relaxation and hyperpolarization, and is believed to be a cytochrome P450 
(CYP450) metabolite of arachidonic acid (AA). Calcium-dependent potassium channel 
blockade with tetraethylamlne (TEA), apamin and charybdotoxin, or CYP450 Inhibition 
with miconazole, are Indwsct, but accepted methods of EDHF antagonism. In this study, 
we tested the hypothesis that thrombin-induced t-PA release is EDHF-dependent. 
Human mwovascular endothelial cells were Incubated in with 2mM sodium butyrate for 
24 hours. Cells were washed and Incubated for 30 minutes I” M199+0.03% albumin and 
inhibitors in triplicate. The cells were then stimulated with 10 U/ml thrombin or vehicle. 
Medium was harvested at multiple time intervals and t-PA antigen was measured by 
ELISA. As expected, in the presence and absence of ASA and L-NAME, thrombin trig- 
gered a significant Induction of t-PA release. TEA had no effect on t-PA release at any 
doses, nor did apamin and charybdotoxin. However, miconazole effectively inhibited 
thrombin-induced t-PA release in a dose-dependent manner (l&=8 nM). The AA epoxy- 
genase inhibitor MS-PPOY inhibited both constitutive and thrombin-induced release oft- 
PA I” a dose-dependent manner. These studies tndlcate that miconazole and MS-PPOH. 
but not potaswm channel blockade, inhibit thrombln-induced t-PA release in the pres- 
ence of ASA and L-NAME. While these methods of EDHF antagonism are indirect, we 
speculate EDHF induces t-PA release through a mechanism independent of calcium- 
dependent K+ channel actwation. 
1032-l 32 Eptifibatide Blocks C-Reactive Protein Increase After 
Coronary Angioplasty 
Alvaro Merino, lanacio Seaurs, Bernat Vidal, Andres Grau. Crlstina Imizcoz, Antonlo 
Rodriguez, Eduardo Alegria, Clinica Rotger, Palma de Mallorca, Span, Clinica 
Universitaria. Pamplona, Spain 
Background: Intraarterial thrombosis and arterial wall inflammation interactions could be 
responsible for the sharp increase in C-reactive protein (CRP) observed in acute core- 
nary syndromes. Thus, we tested the hypothesis that CRP increase in a model of acute 
comnary syndromes such as coronary angioplasty could be due to intraarterial thrombo- 
sis. 
Methods: One hundred twenty-five patients who underwent a camnary angioplasty pro- 
cedure at our cath lab were included. We excluded patients with inflammatory, metabolic 
or neoplastic diseases. Patients with post angioplasty CWMB elevation were also 
excluded. lnflammabon markers studied were: CRP, IL 6, IL-1 b. and plasma macrophage 
colony stimulating factor (MCSF). Blood samples were collected pre angioplasty, 24 and 
48 hours after the procedure. In 71 patients an eptifibatide perfusion was initiated imme- 
diately after the procedure, and continued for only 24 hours. The remaining 54 patients 
received standard antithrombotic therapy. 
Results: CRP figures are shown in the table. IL-6, IL-1 b and MCSF results will be pre- 
sented at the meetina: 
Conclusions: C-r&&e protein increase after coronary angioplasty was suppressed by 
eptifibatide. a svnthetic ceatide which is a selective blocker of the platelet GP Ilb-llla ._ ,, 
receptor with no known anti-inflammatory effects. Thus, it seems that CRP increase in 
acute coronary syndromes could be mostly due to intraarterial thrombosis. 
C-reactive Protein After PTCA 
n Pre-PTCA 24 h 48 h 
Eptifibatlde 71 0.76*1 .I5 0.69rl 1.14*1.13 
Control 54 0.52kO.52 1.08+0.99 1.47e1.38 
P “S pco.oo1 “S 
1032-l 33 Inhibition of Plasminogen Activator Inhibitor Type-l 
Expression in Human Adipose Tissue: An 
Antithrombotic and Antiatherogenic Effect of ANP, 
CNP, and BNP 
Andreas Zirlik. Anne Leughers, Sven van Saldern, Christoph Bode, Burton E. Sobel, 
Thomas K. Nordt. Universitv of Freibura. Freibura. Germanv. Universltv of Vermont 
College of Medicine, Burlington, VT 
-. 
Background: Human adipose tissue produces substantial amounts of plasminogen acti- 
vator inhlbitor type-l (PAI-l), an established risk factor for cardiovascular disease. Little 
is known about natural regulators of PAI- in human adipose tissue. Therefore, the 
present study examines the possible effect of angiotensin II, atrial natwretic peptide 
(ANP). C-type natriuretic peptlde (CNP), and B-type natriuretic peptide (BNP) on PAI- 
expression in human adipose tissue. 
Methods: Human preadipocytes in primary culture were exposed to selected concentra- 
tions of angiotensin II (IOOnM, lpM, IOpM, 1OOpM) as well as ANP, CNP, and BNP 
(IOnM, lOOnM, 1pM) in the presence and absence of transforming growth factor-beta. 
PAI- protein was measured by ELISA, total protein colorimetically, PAI- mRNA by light 
cycler RT-PCR. Parallel experiments were performed in primary cultures of in vitro differ- 
entiated human adipocytes and in human adipose tissue explants. 
Results: Incubation with angiotensin II up to unphysiological doses as high as 100wM did 
not have a significant effect on PAI- secretion in all cell types (n=3). However, ANP, 
CNP, and BNP reduced basal PAI- expression in the conditioned media by up to 
21%*5, 16%*6, and 44%*8 in preadipocytes (1x7, P<O.O5). Stimulation with TGF-beta 
resulted in a lo-fold increase of basal PAI- production (n=7, p<O.OOl). Under stimulated 
conditions ANP, CNP and BNP significantly suppressed PAI- levels by up to 25%i7, 
31%*8, 20%*8 (n=7, P<O.O5). In human adipocytes ANP downregulated TGF-beta 
Induced PAI-1 expression by up to 31%+9, CNP by up to 22%*12, and BNP by up to 
42%+13 (n=5, ~~0.05). Similar results were found I” human adipose tissue explants. 
Total protein quantification indicated persistent viability of cells. Quantification of PAI- 
mRNA suggested that regulation occured at the transcriptional level. 
Conclusions: Anglotensin II does not influence PAI- expression in human adipose tis- 
sue. In contrast, ANP, CNP, and BNP slgnlficantly reduce PAI- expression in all cell 
types. These observations suggest that natriuretic peptides may have an antithrombotic 
and antiatherogenic effect by being natural downregulators of PAI-1, 
